Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings
Bavencio Sees Double-Digit Growth
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
You may also be interested in...
India Biosimilar Cetuximab Go-Ahead: Merck KGaA Wants Data In Public Domain
Merck KGaA calls for data on Indian firm Enzene’s biosimilar cetuximab to be made available in the public domain, citing the Helsinki Declaration.
Merck KGaA Expects Modest Growth Ahead Of Launches Next Year
The German firm is eyeing licensing opportunities in 2023 to fill up its mid-stage pipeline.
Merck KGaA Plumps For Reinvention To Refuel R&D
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.